ESMO 2026

OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Primary Results of SARON: A Randomised-Controlled Trial of Consolidation Radiotherapy for Synchronous Oligometastatic Non-Small Cell Lung Cancer @fifimcdrmh 🫁 Randomized phase II (n=140): first-line SACT ± consolidation radiotherapy in synchronous oligometastatic AGA-negative NSCLC. Endpoints: OS and PFS. ➡️ Median OS 31.0 vs 28.0 mo; HR 0.99 (0.63–1.55); p=0.95 ➡️ Median PFS 13.9 vs 8.9 mo; HR 0.64 (0.43–0.95); p=0.03 ➡️ 12-month local failure 13.0% vs 39.5% (p<0.01); grade ≥3 AEs 28.6% in both arms ✅ SACT + RT achieved better local disease control and longer PFS with acceptable side effects, but this did not translate into survival benefit. 🎙️ Fiona McDonald (4Sight Made from Abstracts publicly available at the ESMO website) Pinging our OncoAlert Lung Cancer Faculty @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers

🔬ESMO 2026 Lung Cancer Abstract Highlights | How are emerging therapies reshaping the lung cancer treatment landscape? These 10 selected phase III studies explore new strategies across #SCLC and #NSCLC, including immunotherapy, next-generation #ADCs and targeted approaches to treatment resistance. 🔹DeLLphi-305 (LBA3): Tarlatamab + durvalumab vs. durvalumab alone as first-line maintenance for ES-SCLC, testing DLL3-directed T-cell engagement earlier in treatment. 🔹OptiTROP-Lung06 (LBA66): Sacituzumab tirumotecan (TROP2 ADC) + pembrolizumab vs. chemotherapy + pembrolizumab in first-line PD-L1-negative advanced nonsquamous NSCLC. 🔹OptiTROP-Lung04 (LBA67): Final overall survival analysis of sacituzumab tirumotecan vs. platinum-based chemotherapy after EGFR-TKI progression in EGFR-mutated NSCLC. 🔹Sigvotatug Vedotin (LBA68): A phase III comparison with docetaxel in previously treated nonsquamous NSCLC, examining efficacy and safety. 🔹KRASCENDO 1 (LBA5): Divarasib vs. sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC, offering a direct comparison within the targeted therapy class. 🔹SAFFRON (LBA6): Osimertinib + savolitinib vs. platinum-pemetrexed after osimertinib progression in EGFR-mutated NSCLC with MET overexpression and/or amplification. 🔹SANOVO (LBA69): Savolitinib + osimertinib vs. osimertinib alone in treatment-naïve EGFR-mutated NSCLC with MET overexpression, exploring upfront dual-target inhibition. 🔹PANKU-Lung01 (LBA71): Izalontamab brengitecan, a bispecific ADC, in EGFR-mutated nonsquamous NSCLC after progression on a third-generation EGFR-TKI. 🔹HERON-Lung01 (LBA72): Ruzaltatug rezetecan, a HER3-directed ADC, vs. platinum-based chemotherapy after EGFR-TKI progression in EGFR-mutated advanced NSCLC. 🔹Neotorch (LBA64): Final analysis of perioperative toripalimab + chemotherapy in resectable stage II-III NSCLC, focusing on long-term outcomes. 🔗Read more: https://oncodaily.com/oncolibrary/lung-oncology/esmo-2026-lung 💡MedChemExpress offers 3900+ tools for lung cancer research: https://www.medchemexpress.com/disease-areas/lung-cancer.html #ESMO26 #ESMO2026 #ESMO #LungCancer #CancerResearch #Oncology